| Erik Christian Stabell, MD | |
|
1 Professional Dr, Suite 220, Alton, IL 62002-5068 | |
| (618) 463-8610 | |
| (618) 463-8688 |
| Full Name | Erik Christian Stabell |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 41 Years |
| Location | 1 Professional Dr, Alton, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609868108 | NPI | - | NPPES |
| 036069182 | Medicaid | IL | |
| 207945908 | Medicaid | MO | |
| 207219 | Other | IL | PTAN |
| Facility Name | Location | Facility Type |
|---|---|---|
| Christian Hospital Northeast | Saint louis, MO | Hospital |
| Alton Memorial Hospital | Alton, IL | Hospital |
| Jersey Community Hospital | Jerseyville, IL | Hospital |
| Osf Saint Anthony's Health Center | Alton, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alton Memorial Physician Billing Services Llc | 9436389442 | 19 |
News Archive
Patient age and gender have a significant effect on the risk for revisions after primary total hip replacement, show study findings.
Adolescents are more likely to say they will try electronic cigarettes if they perceive TV ads for these products as effective, according to a new study by RTI International researchers.
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that while approximately 70 percent of surveyed physicians' newly diagnosed patients have mild-to-moderate Alzheimer's disease, only 52.2 percent of first-line patients are prescribed an acetylcholinesterase inhibitor.
Akebia Therapeutics, Inc., a small molecule discovery and development company focused on anemia and vascular disorders, today announced that it has dosed the first subjects in a first-in-man Phase 1 study of AKB-9778, a first-in-class human protein tyrosine phosphatase beta (HPTPβ) inhibitor in development for diabetic macular edema (DME) and diabetic retinopathy (DR).
› Verified 4 days ago
| Entity Name | Alton Multispecialists Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942312442 PECOS PAC ID: 0840194882 Enrollment ID: O20031121000610 |
News Archive
Patient age and gender have a significant effect on the risk for revisions after primary total hip replacement, show study findings.
Adolescents are more likely to say they will try electronic cigarettes if they perceive TV ads for these products as effective, according to a new study by RTI International researchers.
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that while approximately 70 percent of surveyed physicians' newly diagnosed patients have mild-to-moderate Alzheimer's disease, only 52.2 percent of first-line patients are prescribed an acetylcholinesterase inhibitor.
Akebia Therapeutics, Inc., a small molecule discovery and development company focused on anemia and vascular disorders, today announced that it has dosed the first subjects in a first-in-man Phase 1 study of AKB-9778, a first-in-class human protein tyrosine phosphatase beta (HPTPβ) inhibitor in development for diabetic macular edema (DME) and diabetic retinopathy (DR).
› Verified 4 days ago
| Entity Name | Alton Memorial Physician Billing Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558783647 PECOS PAC ID: 9436389442 Enrollment ID: O20140312001531 |
News Archive
Patient age and gender have a significant effect on the risk for revisions after primary total hip replacement, show study findings.
Adolescents are more likely to say they will try electronic cigarettes if they perceive TV ads for these products as effective, according to a new study by RTI International researchers.
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that while approximately 70 percent of surveyed physicians' newly diagnosed patients have mild-to-moderate Alzheimer's disease, only 52.2 percent of first-line patients are prescribed an acetylcholinesterase inhibitor.
Akebia Therapeutics, Inc., a small molecule discovery and development company focused on anemia and vascular disorders, today announced that it has dosed the first subjects in a first-in-man Phase 1 study of AKB-9778, a first-in-class human protein tyrosine phosphatase beta (HPTPβ) inhibitor in development for diabetic macular edema (DME) and diabetic retinopathy (DR).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Erik Christian Stabell, MD 1 Professional Dr Suite 220, Alton, IL 62002-5068 Ph: (618) 463-8500 | Erik Christian Stabell, MD 1 Professional Dr, Suite 220, Alton, IL 62002-5068 Ph: (618) 463-8610 |
News Archive
Patient age and gender have a significant effect on the risk for revisions after primary total hip replacement, show study findings.
Adolescents are more likely to say they will try electronic cigarettes if they perceive TV ads for these products as effective, according to a new study by RTI International researchers.
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that while approximately 70 percent of surveyed physicians' newly diagnosed patients have mild-to-moderate Alzheimer's disease, only 52.2 percent of first-line patients are prescribed an acetylcholinesterase inhibitor.
Akebia Therapeutics, Inc., a small molecule discovery and development company focused on anemia and vascular disorders, today announced that it has dosed the first subjects in a first-in-man Phase 1 study of AKB-9778, a first-in-class human protein tyrosine phosphatase beta (HPTPβ) inhibitor in development for diabetic macular edema (DME) and diabetic retinopathy (DR).
› Verified 4 days ago
Ibrahim B.i. Elayyan, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Saint Anthonys Way, Alton, IL 62002 Phone: 314-317-0600 Fax: 314-317-0606 | |
Dr. Barry Michael Mossman, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2 Memorial Dr, Ste 220, Alton, IL 62002 Phone: 618-474-1723 Fax: 618-474-6989 | |
Dr. Matthew Austin Nations, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Memorial Dr, Alton, IL 62002 Phone: 618-463-7240 | |
Mr. David Robert Riedel, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4 Memorial Dr Ste 230, Alton, IL 62002 Phone: 618-463-7874 Fax: 618-463-7846 | |
Dr. Stanley J Sidwell Iv, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1 Memorial Dr, Alton, IL 62002 Phone: 618-463-7240 Fax: 618-463-7216 | |
Dr. Edward B Blair Jr., M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2 Saint Anthonys Way, Suite 205, Alton, IL 62002 Phone: 618-462-2222 Fax: 618-463-5004 | |
Dr. William Ray Bartley, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Professional Dr, Suite 220, Alton, IL 62002 Phone: 618-463-8626 Fax: 618-463-8688 |